APO Research
Talk to an analyst

APO RESEARCH · REPORT

Attenuated Vaccine for Human Rabies

Compare research editions
View pricing & licenses

Selected research

Industry Research

Attenuated Vaccine for Human Rabies Industry Research Report 2026

29 December 2025137 pages

Choose your research edition.

Industry ResearchAttenuated Vaccine for Human Rabies Industry Research Report 2026137 pages · $2,950 USDIndustry Growth & TrendsGlobal Attenuated Vaccine for Human Rabies Industry Growth and Trends Forecast to 2032119 pages · $3,450 USDMarket StructureGlobal Attenuated Vaccine for Human Rabies Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032197 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Attenuated Vaccine for Human Rabies Market Outlook and Growth Opportunities 2026194 pages · $4,250 USDMarket Analysis & ForecastGlobal Attenuated Vaccine for Human Rabies Market Analysis and Forecast 2026-2032197 pages · $4,950 USD

Market perspective

The global Attenuated Vaccine for Human Rabies market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.

The North America market for Attenuated Vaccine for Human Rabies is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026–2032.

The Europe market for Attenuated Vaccine for Human Rabies is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032.

Read the full market overview

The Asia Pacific market for Attenuated Vaccine for Human Rabies is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032.

Leading global manufacturers of Attenuated Vaccine for Human Rabies include Changchun Zhuoyi Biological Co., Ltd, Wuhan Institute of Biological Products Co., Ltd, Shandong Yidu Biotechnology Co., Ltd, Ningbo Rongan Biopharmaceutical Co., Ltd, Liaoning Yisheng Biopharmaceutical Co., Ltd, Lanzhou Institute of Biological Products Co., Ltd, Guangzhou Nuocheng Biological Products Co., Ltd, Chengdu Kanghua Biological Products Co., Ltd and AstraZeneca, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

Report Scope

This report quantifies the global Attenuated Vaccine for Human Rabies market in terms of revenue (US$ million) and, where applicable, sales volume (K Units), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.

It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/K Units) and concentration ratios (CR5/CR10).

The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.

Key Companies & Market Share Insights

This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.

Attenuated Vaccine for Human Rabies Market by Company

Changchun Zhuoyi Biological Co., Ltd

Wuhan Institute of Biological Products Co., Ltd

Shandong Yidu Biotechnology Co., Ltd

Ningbo Rongan Biopharmaceutical Co., Ltd

Liaoning Yisheng Biopharmaceutical Co., Ltd

Lanzhou Institute of Biological Products Co., Ltd

Guangzhou Nuocheng Biological Products Co., Ltd

Chengdu Kanghua Biological Products Co., Ltd

AstraZeneca

Sanofi Pasteur, Inc

Pfizer Inc

Novartis AG

Merck & Co Inc

GlaxoSmithKline

Cadila Pharmaceuticals Ltd

Attenuated Vaccine for Human Rabies Segment by Type

Vero Cell

Human Diploid Cell

Attenuated Vaccine for Human Rabies Segment by Application

Hospital

Clinic

Attenuated Vaccine for Human Rabies Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Attenuated Vaccine for Human Rabies market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Attenuated Vaccine for Human Rabies and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market

5. This report helps stakeholders to gain insights into which regions to target globally

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Attenuated Vaccine for Human Rabies.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Research objectives, research methods, data sources, data cross-validation;

Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 3: Detailed analysis of Attenuated Vaccine for Human Rabies manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.

Chapter 5: Production/output, value of Attenuated Vaccine for Human Rabies by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.

Chapter 6: Consumption of Attenuated Vaccine for Human Rabies in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.

Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 11: The main points and conclusions of the report.

More report detail

Tables and figures
List of Tables Table 1. Secondary Sources Table 2. Primary Sources Table 3. Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million) Table 4. Market Value Comparison by Application (2021 VS 2025 VS 2032) & (US$ Million) Table 5. Global Attenuated Vaccine for Human Rabies Volume and Revenue Market Size and CAGR of Manufacturers (2021 Versus 2025) Table 6. Global Attenuated Vaccine for Human Rabies Sales (K Units) of Manufacturers (2021-2026) Table 7. Global Attenuated Vaccine for Human Rabies Sales Market Share by Manufacturers (2021-2026) Table 8. Global Attenuated Vaccine for Human Rabies Revenue of Manufacturers (2021-2026) Table 9. Global Attenuated Vaccine for Human Rabies Revenue Share by Manufacturers (2021-2026) Table 10. Global Market Attenuated Vaccine for Human Rabies Average Price (US$/Unit) of Manufacturers (2021-2026) Table 11. Global Attenuated Vaccine for Human Rabies Industry Ranking, 2024 VS 2025 VS 2026 Table 12. Global Manufacturers of Attenuated Vaccine for Human Rabies, Manufacturing Sites & Headquarters Table 13. Global Manufacturers of Attenuated Vaccine for Human Rabies, Product Type & Application Table 14. Global Attenuated Vaccine for Human Rabies Manufacturers Established Date Table 15. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 16. Global Attenuated Vaccine for Human Rabies by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 17. Manufacturers Mergers & Acquisitions, Expansion Plans) Table 18. Changchun Zhuoyi Biological Co., Ltd Company Information Table 19. Changchun Zhuoyi Biological Co., Ltd Business Overview Table 20. Changchun Zhuoyi Biological Co., Ltd Attenuated Vaccine for Human Rabies Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 21. Changchun Zhuoyi Biological Co., Ltd Attenuated Vaccine for Human Rabies Product Portfolio Table 22. Changchun Zhuoyi Biological Co., Ltd Recent Developments Table 23. Wuhan Institute of Biological Products Co., Ltd Company Information Table 24. Wuhan Institute of Biological Products Co., Ltd Business Overview Table 25. Wuhan Institute of Biological Products Co., Ltd Attenuated Vaccine for Human Rabies Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 26. Wuhan Institute of Biological Products Co., Ltd Attenuated Vaccine for Human Rabies Product Portfolio Table 27. Wuhan Institute of Biological Products Co., Ltd Recent Developments Table 28. Shandong Yidu Biotechnology Co., Ltd Company Information Table 29. Shandong Yidu Biotechnology Co., Ltd Business Overview Table 30. Shandong Yidu Biotechnology Co., Ltd Attenuated Vaccine for Human Rabies Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 31. Shandong Yidu Biotechnology Co., Ltd Attenuated Vaccine for Human Rabies Product Portfolio Table 32. Shandong Yidu Biotechnology Co., Ltd Recent Developments Table 33. Ningbo Rongan Biopharmaceutical Co., Ltd Company Information Table 34. Ningbo Rongan Biopharmaceutical Co., Ltd Business Overview Table 35. Ningbo Rongan Biopharmaceutical Co., Ltd Attenuated Vaccine for Human Rabies Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 36. Ningbo Rongan Biopharmaceutical Co., Ltd Attenuated Vaccine for Human Rabies Product Portfolio Table 37. Ningbo Rongan Biopharmaceutical Co., Ltd Recent Developments Table 38. Liaoning Yisheng Biopharmaceutical Co., Ltd Company Information Table 39. Liaoning Yisheng Biopharmaceutical Co., Ltd Business Overview Table 40. Liaoning Yisheng Biopharmaceutical Co., Ltd Attenuated Vaccine for Human Rabies Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 41. Liaoning Yisheng Biopharmaceutical Co., Ltd Attenuated Vaccine for Human Rabies Product Portfolio Table 42. Liaoning Yisheng Biopharmaceutical Co., Ltd Recent Developments Table 43. Lanzhou Institute of Biological Products Co., Ltd Company Information Table 44. Lanzhou Institute of Biological Products Co., Ltd Business Overview Table 45. Lanzhou Institute of Biological Products Co., Ltd Attenuated Vaccine for Human Rabies Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 46. Lanzhou Institute of Biological Products Co., Ltd Attenuated Vaccine for Human Rabies Product Portfolio Table 47. Lanzhou Institute of Biological Products Co., Ltd Recent Developments Table 48. Guangzhou Nuocheng Biological Products Co., Ltd Company Information Table 49. Guangzhou Nuocheng Biological Products Co., Ltd Business Overview Table 50. Guangzhou Nuocheng Biological Products Co., Ltd Attenuated Vaccine for Human Rabies Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 51. Guangzhou Nuocheng Biological Products Co., Ltd Attenuated Vaccine for Human Rabies Product Portfolio Table 52. Guangzhou Nuocheng Biological Products Co., Ltd Recent Developments Table 53. Chengdu Kanghua Biological Products Co., Ltd Company Information Table 54. Chengdu Kanghua Biological Products Co., Ltd Business Overview Table 55. Chengdu Kanghua Biological Products Co., Ltd Attenuated Vaccine for Human Rabies Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 56. Chengdu Kanghua Biological Products Co., Ltd Attenuated Vaccine for Human Rabies Product Portfolio Table 57. Chengdu Kanghua Biological Products Co., Ltd Recent Developments Table 58. AstraZeneca Company Information Table 59. AstraZeneca Business Overview Table 60. AstraZeneca Attenuated Vaccine for Human Rabies Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 61. AstraZeneca Attenuated Vaccine for Human Rabies Product Portfolio Table 62. AstraZeneca Recent Developments Table 63. Sanofi Pasteur, Inc Company Information Table 64. Sanofi Pasteur, Inc Business Overview Table 65. Sanofi Pasteur, Inc Attenuated Vaccine for Human Rabies Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 66. Sanofi Pasteur, Inc Attenuated Vaccine for Human Rabies Product Portfolio Table 67. Sanofi Pasteur, Inc Recent Developments Table 68. Pfizer Inc Company Information Table 69. Pfizer Inc Business Overview Table 70. Pfizer Inc Attenuated Vaccine for Human Rabies Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 71. Pfizer Inc Attenuated Vaccine for Human Rabies Product Portfolio Table 72. Pfizer Inc Recent Developments Table 73. Novartis AG Company Information Table 74. Novartis AG Business Overview Table 75. Novartis AG Attenuated Vaccine for Human Rabies Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 76. Novartis AG Attenuated Vaccine for Human Rabies Product Portfolio Table 77. Novartis AG Recent Developments Table 78. Merck & Co Inc Company Information Table 79. Merck & Co Inc Business Overview Table 80. Merck & Co Inc Attenuated Vaccine for Human Rabies Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 81. Merck & Co Inc Attenuated Vaccine for Human Rabies Product Portfolio Table 82. Merck & Co Inc Recent Developments Table 83. GlaxoSmithKline Company Information Table 84. GlaxoSmithKline Business Overview Table 85. GlaxoSmithKline Attenuated Vaccine for Human Rabies Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 86. GlaxoSmithKline Attenuated Vaccine for Human Rabies Product Portfolio Table 87. GlaxoSmithKline Recent Developments Table 88. Cadila Pharmaceuticals Ltd Company Information Table 89. Cadila Pharmaceuticals Ltd Business Overview Table 90. Cadila Pharmaceuticals Ltd Attenuated Vaccine for Human Rabies Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 91. Cadila Pharmaceuticals Ltd Attenuated Vaccine for Human Rabies Product Portfolio Table 92. Cadila Pharmaceuticals Ltd Recent Developments Table 93. Global Attenuated Vaccine for Human Rabies Market Size by Region (US$ Million): 2021 VS 2025 VS 2032 Table 94. Global Attenuated Vaccine for Human Rabies Sales by Region (2021-2026) & (K Units) Table 95. Global Attenuated Vaccine for Human Rabies Sales Market Share by Region (2021-2026) Table 96. Global Attenuated Vaccine for Human Rabies Sales by Region (2027-2032) & (K Units) Table 97. Global Attenuated Vaccine for Human Rabies Sales Market Share by Region (2027-2032) Table 98. Global Attenuated Vaccine for Human Rabies Revenue by Region (2021-2026) & (US$ Million) Table 99. Global Attenuated Vaccine for Human Rabies Revenue Market Share by Region (2021-2026) Table 100. Global Attenuated Vaccine for Human Rabies Revenue by Region (2027-2032) & (US$ Million) Table 101. Global Attenuated Vaccine for Human Rabies Revenue Market Share by Region (2027-2032) Table 102. North America Attenuated Vaccine for Human Rabies Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 103. North America Attenuated Vaccine for Human Rabies Sales by Country (2021-2026) & (K Units) Table 104. North America Attenuated Vaccine for Human Rabies Sales by Country (2027-2032) & (K Units) Table 105. North America Attenuated Vaccine for Human Rabies Revenue by Country (2021-2026) & (US$ Million) Table 106. North America Attenuated Vaccine for Human Rabies Revenue by Country (2027-2032) & (US$ Million) Table 107. Europe Attenuated Vaccine for Human Rabies Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 108. Europe Attenuated Vaccine for Human Rabies Sales by Country (2021-2026) & (K Units) Table 109. Europe Attenuated Vaccine for Human Rabies Sales by Country (2027-2032) & (K Units) Table 110. Europe Attenuated Vaccine for Human Rabies Revenue by Country (2021-2026) & (US$ Million) Table 111. Europe Attenuated Vaccine for Human Rabies Revenue by Country (2027-2032) & (US$ Million) Table 112. Asia Pacific Attenuated Vaccine for Human Rabies Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 113. Asia Pacific Attenuated Vaccine for Human Rabies Sales by Country (2021-2026) & (K Units) Table 114. Asia Pacific Attenuated Vaccine for Human Rabies Sales by Country (2027-2032) & (K Units) Table 115. Asia Pacific Attenuated Vaccine for Human Rabies Revenue by Country (2021-2026) & (US$ Million) Table 116. Asia Pacific Attenuated Vaccine for Human Rabies Revenue by Country (2027-2032) & (US$ Million) Table 117. South America Attenuated Vaccine for Human Rabies Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 118. South America Attenuated Vaccine for Human Rabies Sales by Country (2021-2026) & (K Units) Table 119. South America Attenuated Vaccine for Human Rabies Sales by Country (2027-2032) & (K Units) Table 120. South America Attenuated Vaccine for Human Rabies Revenue by Country (2021-2026) & (US$ Million) Table 121. South America Attenuated Vaccine for Human Rabies Revenue by Country (2027-2032) & (US$ Million) Table 122. Middle East and Africa Attenuated Vaccine for Human Rabies Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 123. Middle East and Africa Attenuated Vaccine for Human Rabies Sales by Country (2021-2026) & (K Units) Table 124. Middle East and Africa Attenuated Vaccine for Human Rabies Sales by Country (2027-2032) & (K Units) Table 125. Middle East and Africa Attenuated Vaccine for Human Rabies Revenue by Country (2021-2026) & (US$ Million) Table 126. Middle East and Africa Attenuated Vaccine for Human Rabies Revenue by Country (2027-2032) & (US$ Million) Table 127. Global Attenuated Vaccine for Human Rabies Sales by Type (2021-2026) & (K Units) Table 128. Global Attenuated Vaccine for Human Rabies Sales by Type (2027-2032) & (K Units) Table 129. Global Attenuated Vaccine for Human Rabies Sales Market Share by Type (2021-2026) Table 130. Global Attenuated Vaccine for Human Rabies Sales Market Share by Type (2027-2032) Table 131. Global Attenuated Vaccine for Human Rabies Revenue by Type (2021-2026) & (US$ Million) Table 132. Global Attenuated Vaccine for Human Rabies Revenue by Type (2027-2032) & (US$ Million) Table 133. Global Attenuated Vaccine for Human Rabies Revenue Market Share by Type (2021-2026) Table 134. Global Attenuated Vaccine for Human Rabies Revenue Market Share by Type (2027-2032) Table 135. Global Attenuated Vaccine for Human Rabies Price by Type (2021-2026) & (US$/Unit) Table 136. Global Attenuated Vaccine for Human Rabies Price by Type (2027-2032) & (US$/Unit) Table 137. Global Attenuated Vaccine for Human Rabies Sales by Application (2021-2026) & (K Units) Table 138. Global Attenuated Vaccine for Human Rabies Sales by Application (2027-2032) & (K Units) Table 139. Global Attenuated Vaccine for Human Rabies Sales Market Share by Application (2021-2026) Table 140. Global Attenuated Vaccine for Human Rabies Sales Market Share by Application (2027-2032) Table 141. Global Attenuated Vaccine for Human Rabies Revenue by Application (2021-2026) & (US$ Million) Table 142. Global Attenuated Vaccine for Human Rabies Revenue by Application (2027-2032) & (US$ Million) Table 143. Global Attenuated Vaccine for Human Rabies Revenue Market Share by Application (2021-2026) Table 144. Global Attenuated Vaccine for Human Rabies Revenue Market Share by Application (2027-2032) Table 145. Global Attenuated Vaccine for Human Rabies Price by Application (2021-2026) & (US$/Unit) Table 146. Global Attenuated Vaccine for Human Rabies Price by Application (2027-2032) & (US$/Unit) Table 147. Key Raw Materials Table 148. Raw Materials Key Suppliers Table 149. Attenuated Vaccine for Human Rabies Distributors List Table 150. Attenuated Vaccine for Human Rabies Customers List Table 151. Attenuated Vaccine for Human Rabies Industry Trends Table 152. Attenuated Vaccine for Human Rabies Industry Drivers Table 153. Attenuated Vaccine for Human Rabies Industry Restraints Table 154. Authors List of This Report List of Figures Figure 1. Research Methodology Figure 2. Research Process Figure 3. Key Executives Interviewed Figure 4. Attenuated Vaccine for Human Rabies Product Image Figure 5. Global Attenuated Vaccine for Human Rabies Revenue (US$ Million), 2021 VS 2025 VS 2032 Figure 6. Global Attenuated Vaccine for Human Rabies Market Size (2021-2032) & (US$ Million) Figure 7. Global Attenuated Vaccine for Human Rabies Sales (2021-2032) & (K Units) Figure 8. Global Attenuated Vaccine for Human Rabies Average Price (US$/Unit) & (2021-2032) Figure 9. Vero Cell Product Image Figure 10. Human Diploid Cell Product Image Figure 11. Hospital Product Image Figure 12. Clinic Product Image Figure 13. Global Attenuated Vaccine for Human Rabies Revenue Share by Manufacturers in 2025 Figure 14. Global Manufacturers of Attenuated Vaccine for Human Rabies, Manufacturing Sites & Headquarters Figure 15. Global Top 5 and 10 Attenuated Vaccine for Human Rabies Players Market Share by Revenue in 2025 Figure 16. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 17. Global Attenuated Vaccine for Human Rabies Market Size by Region (US$ Million): 2021 VS 2025 VS 2032 Figure 18. Global Attenuated Vaccine for Human Rabies Sales by Region in 2025 Figure 19. Global Attenuated Vaccine for Human Rabies Revenue by Region in 2025 Figure 20. North America Attenuated Vaccine for Human Rabies Market Size by Country in 2025 Figure 21. North America Attenuated Vaccine for Human Rabies Sales Market Share by Country (2021-2032) Figure 22. North America Attenuated Vaccine for Human Rabies Revenue Market Share by Country (2021-2032) Figure 23. United States Attenuated Vaccine for Human Rabies Revenue Growth Rate (2021-2032) & (US$ Million) Figure 24. Canada Attenuated Vaccine for Human Rabies Revenue Growth Rate (2021-2032) & (US$ Million) Figure 25. Europe Attenuated Vaccine for Human Rabies Market Size by Country in 2025 Figure 26. Europe Attenuated Vaccine for Human Rabies Sales Market Share by Country (2021-2032) Figure 27. Europe Attenuated Vaccine for Human Rabies Revenue Market Share by Country (2021-2032) Figure 28. Germany Attenuated Vaccine for Human Rabies Revenue Growth Rate (2021-2032) & (US$ Million) Figure 29. France Attenuated Vaccine for Human Rabies Revenue Growth Rate (2021-2032) & (US$ Million) Figure 30. U.K. Attenuated Vaccine for Human Rabies Revenue Growth Rate (2021-2032) & (US$ Million) Figure 31. Italy Attenuated Vaccine for Human Rabies Revenue Growth Rate (2021-2032) & (US$ Million) Figure 32. Netherlands Attenuated Vaccine for Human Rabies Revenue Growth Rate (2021-2032) & (US$ Million) Figure 33. Asia Pacific Attenuated Vaccine for Human Rabies Market Size by Country in 2025 Figure 34. Asia Pacific Attenuated Vaccine for Human Rabies Sales Market Share by Country (2021-2032) Figure 35. Asia Pacific Attenuated Vaccine for Human Rabies Revenue Market Share by Country (2021-2032) Figure 36. China Attenuated Vaccine for Human Rabies Revenue Growth Rate (2021-2032) & (US$ Million) Figure 37. Japan Attenuated Vaccine for Human Rabies Revenue Growth Rate (2021-2032) & (US$ Million) Figure 38. South Korea Attenuated Vaccine for Human Rabies Revenue Growth Rate (2021-2032) & (US$ Million) Figure 39. India Attenuated Vaccine for Human Rabies Revenue Growth Rate (2021-2032) & (US$ Million) Figure 40. Australia Attenuated Vaccine for Human Rabies Revenue Growth Rate (2021-2032) & (US$ Million) Figure 41. China Taiwan Attenuated Vaccine for Human Rabies Revenue Growth Rate (2021-2032) & (US$ Million) Figure 42. Southeast Asia Attenuated Vaccine for Human Rabies Revenue Growth Rate (2021-2032) & (US$ Million) Figure 43. Southeast Asia Attenuated Vaccine for Human Rabies Revenue Growth Rate (2021-2032) & (US$ Million) Figure 44. South America Attenuated Vaccine for Human Rabies Market Size by Country in 2025 Figure 45. South America Attenuated Vaccine for Human Rabies Sales Market Share by Country (2021-2032) Figure 46. South America Attenuated Vaccine for Human Rabies Revenue Market Share by Country (2021-2032) Figure 47. Mexico Attenuated Vaccine for Human Rabies Revenue Growth Rate (2021-2032) & (US$ Million) Figure 48. Brazil Attenuated Vaccine for Human Rabies Revenue Growth Rate (2021-2032) & (US$ Million) Figure 49. Argentina Attenuated Vaccine for Human Rabies Revenue Growth Rate (2021-2032) & (US$ Million) Figure 50. Middle East and Africa Attenuated Vaccine for Human Rabies Market Size by Country in 2025 Figure 51. Middle East and Africa Attenuated Vaccine for Human Rabies Sales Market Share by Country (2021-2032) Figure 52. Middle East and Africa Attenuated Vaccine for Human Rabies Revenue Market Share by Country (2021-2032) Figure 53. Turkey Attenuated Vaccine for Human Rabies Revenue Growth Rate (2021-2032) & (US$ Million) Figure 54. Saudi Arabia Attenuated Vaccine for Human Rabies Revenue Growth Rate (2021-2032) & (US$ Million) Figure 55. UAE Attenuated Vaccine for Human Rabies Revenue Growth Rate (2021-2032) & (US$ Million) Figure 56. Global Attenuated Vaccine for Human Rabies Sales Market Share by Type (2021-2032) Figure 57. Global Attenuated Vaccine for Human Rabies Revenue Market Share by Type (2021-2032) Figure 58. Global Attenuated Vaccine for Human Rabies Price (US$/Unit) by Type (2021-2032) Figure 59. Global Attenuated Vaccine for Human Rabies Sales Market Share by Application (2021-2032) Figure 60. Global Attenuated Vaccine for Human Rabies Revenue Market Share by Application (2021-2032) Figure 61. Global Attenuated Vaccine for Human Rabies Price (US$/Unit) by Application (2021-2032) Figure 62. Attenuated Vaccine for Human Rabies Value Chain Figure 63. Attenuated Vaccine for Human Rabies Production Mode & Process Figure 64. Direct Comparison with Distribution Share Figure 65. Distributors Profiles Figure 66. Attenuated Vaccine for Human Rabies Industry Opportunities and Challenges

Scope & coverage.

Types
  • Vero Cell
  • Human Diploid Cell
Applications
  • Hospital
  • Clinic
Companies covered
  • Changchun Zhuoyi Biological Co., Ltd
  • Wuhan Institute of Biological Products Co., Ltd
  • Shandong Yidu Biotechnology Co., Ltd
  • Ningbo Rongan Biopharmaceutical Co., Ltd
  • Liaoning Yisheng Biopharmaceutical Co., Ltd
  • Lanzhou Institute of Biological Products Co., Ltd
  • Guangzhou Nuocheng Biological Products Co., Ltd
  • Chengdu Kanghua Biological Products Co., Ltd
  • AstraZeneca
  • Sanofi Pasteur, Inc
  • Pfizer Inc
  • Novartis AG
  • Merck & Co Inc
  • GlaxoSmithKline
  • Cadila Pharmaceuticals Ltd

Inside the report.

1 Preface
  1. 1.1 Scope of Report
  2. 1.2 Reasons for Doing This Study
  3. 1.3 Research Methodology
  4. 1.4 Research Process
  5. 1.5 Data Source
  6. 1.5.1 Secondary Sources
  7. 1.5.2 Primary Sources
2 Market Overview
  1. 2.1 Product Definition
  2. 2.2 Global Market Growth Prospects
  3. 2.2.1 Global Attenuated Vaccine for Human Rabies Market Size (2021-2032)
  4. 2.2.2 Global Attenuated Vaccine for Human Rabies Sales (2021-2032)
  5. 2.2.3 Global Attenuated Vaccine for Human Rabies Market Average Price (2021-2032)
  6. 2.3 Attenuated Vaccine for Human Rabies by Type
  7. 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
  8. 2.3.2 Vero Cell
  9. 2.3.3 Human Diploid Cell
  10. 2.4 Attenuated Vaccine for Human Rabies by Application
  11. 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
  12. 2.4.2 Hospital
  13. 2.4.3 Clinic
3 Market Competitive Landscape by Manufacturers
  1. 3.1 Global Attenuated Vaccine for Human Rabies Market Competitive Situation by Manufacturers (2021 Versus 2025)
  2. 3.2 Global Attenuated Vaccine for Human Rabies Sales (K Units) of Manufacturers (2021-2026)
  3. 3.3 Global Attenuated Vaccine for Human Rabies Revenue of Manufacturers (2021-2026)
  4. 3.4 Global Attenuated Vaccine for Human Rabies Average Price by Manufacturers (2021-2026)
  5. 3.5 Global Attenuated Vaccine for Human Rabies Industry Ranking, 2024 VS 2025 VS 2026
  6. 3.6 Global Manufacturers of Attenuated Vaccine for Human Rabies, Manufacturing Sites & Headquarters
  7. 3.7 Global Manufacturers of Attenuated Vaccine for Human Rabies, Product Type & Application
  8. 3.8 Global Manufacturers of Attenuated Vaccine for Human Rabies, Established Date
  9. 3.9 Global Attenuated Vaccine for Human Rabies Market CR5 and HHI
  10. 3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
  1. 4.1 Changchun Zhuoyi Biological Co., Ltd
  2. 4.1.1 Changchun Zhuoyi Biological Co., Ltd Company Information
  3. 4.1.2 Changchun Zhuoyi Biological Co., Ltd Business Overview
  4. 4.1.3 Changchun Zhuoyi Biological Co., Ltd Attenuated Vaccine for Human Rabies Sales, Revenue and Gross Margin (2021-2026)
  5. 4.1.4 Changchun Zhuoyi Biological Co., Ltd Attenuated Vaccine for Human Rabies Product Portfolio
  6. 4.1.5 Changchun Zhuoyi Biological Co., Ltd Recent Developments
  7. 4.2 Wuhan Institute of Biological Products Co., Ltd
  8. 4.2.1 Wuhan Institute of Biological Products Co., Ltd Company Information
  9. 4.2.2 Wuhan Institute of Biological Products Co., Ltd Business Overview
  10. 4.2.3 Wuhan Institute of Biological Products Co., Ltd Attenuated Vaccine for Human Rabies Sales, Revenue and Gross Margin (2021-2026)
  11. 4.2.4 Wuhan Institute of Biological Products Co., Ltd Attenuated Vaccine for Human Rabies Product Portfolio
  12. 4.2.5 Wuhan Institute of Biological Products Co., Ltd Recent Developments
  13. 4.3 Shandong Yidu Biotechnology Co., Ltd
  14. 4.3.1 Shandong Yidu Biotechnology Co., Ltd Company Information
  15. 4.3.2 Shandong Yidu Biotechnology Co., Ltd Business Overview
  16. 4.3.3 Shandong Yidu Biotechnology Co., Ltd Attenuated Vaccine for Human Rabies Sales, Revenue and Gross Margin (2021-2026)
  17. 4.3.4 Shandong Yidu Biotechnology Co., Ltd Attenuated Vaccine for Human Rabies Product Portfolio
  18. 4.3.5 Shandong Yidu Biotechnology Co., Ltd Recent Developments
  19. 4.4 Ningbo Rongan Biopharmaceutical Co., Ltd
  20. 4.4.1 Ningbo Rongan Biopharmaceutical Co., Ltd Company Information
  21. 4.4.2 Ningbo Rongan Biopharmaceutical Co., Ltd Business Overview
  22. 4.4.3 Ningbo Rongan Biopharmaceutical Co., Ltd Attenuated Vaccine for Human Rabies Sales, Revenue and Gross Margin (2021-2026)
  23. 4.4.4 Ningbo Rongan Biopharmaceutical Co., Ltd Attenuated Vaccine for Human Rabies Product Portfolio
  24. 4.4.5 Ningbo Rongan Biopharmaceutical Co., Ltd Recent Developments
  25. 4.5 Liaoning Yisheng Biopharmaceutical Co., Ltd
  26. 4.5.1 Liaoning Yisheng Biopharmaceutical Co., Ltd Company Information
  27. 4.5.2 Liaoning Yisheng Biopharmaceutical Co., Ltd Business Overview
  28. 4.5.3 Liaoning Yisheng Biopharmaceutical Co., Ltd Attenuated Vaccine for Human Rabies Sales, Revenue and Gross Margin (2021-2026)
  29. 4.5.4 Liaoning Yisheng Biopharmaceutical Co., Ltd Attenuated Vaccine for Human Rabies Product Portfolio
  30. 4.5.5 Liaoning Yisheng Biopharmaceutical Co., Ltd Recent Developments
  31. 4.6 Lanzhou Institute of Biological Products Co., Ltd
  32. 4.6.1 Lanzhou Institute of Biological Products Co., Ltd Company Information
  33. 4.6.2 Lanzhou Institute of Biological Products Co., Ltd Business Overview
  34. 4.6.3 Lanzhou Institute of Biological Products Co., Ltd Attenuated Vaccine for Human Rabies Sales, Revenue and Gross Margin (2021-2026)
  35. 4.6.4 Lanzhou Institute of Biological Products Co., Ltd Attenuated Vaccine for Human Rabies Product Portfolio
  36. 4.6.5 Lanzhou Institute of Biological Products Co., Ltd Recent Developments
  37. 4.7 Guangzhou Nuocheng Biological Products Co., Ltd
  38. 4.7.1 Guangzhou Nuocheng Biological Products Co., Ltd Company Information
  39. 4.7.2 Guangzhou Nuocheng Biological Products Co., Ltd Business Overview
  40. 4.7.3 Guangzhou Nuocheng Biological Products Co., Ltd Attenuated Vaccine for Human Rabies Sales, Revenue and Gross Margin (2021-2026)
  41. 4.7.4 Guangzhou Nuocheng Biological Products Co., Ltd Attenuated Vaccine for Human Rabies Product Portfolio
  42. 4.7.5 Guangzhou Nuocheng Biological Products Co., Ltd Recent Developments
  43. 4.8 Chengdu Kanghua Biological Products Co., Ltd
  44. 4.8.1 Chengdu Kanghua Biological Products Co., Ltd Company Information
  45. 4.8.2 Chengdu Kanghua Biological Products Co., Ltd Business Overview
  46. 4.8.3 Chengdu Kanghua Biological Products Co., Ltd Attenuated Vaccine for Human Rabies Sales, Revenue and Gross Margin (2021-2026)
  47. 4.8.4 Chengdu Kanghua Biological Products Co., Ltd Attenuated Vaccine for Human Rabies Product Portfolio
  48. 4.8.5 Chengdu Kanghua Biological Products Co., Ltd Recent Developments
  49. 4.9 AstraZeneca
  50. 4.9.1 AstraZeneca Company Information
  51. 4.9.2 AstraZeneca Business Overview
  52. 4.9.3 AstraZeneca Attenuated Vaccine for Human Rabies Sales, Revenue and Gross Margin (2021-2026)
  53. 4.9.4 AstraZeneca Attenuated Vaccine for Human Rabies Product Portfolio
  54. 4.9.5 AstraZeneca Recent Developments
  55. 4.10 Sanofi Pasteur, Inc
  56. 4.10.1 Sanofi Pasteur, Inc Company Information
  57. 4.10.2 Sanofi Pasteur, Inc Business Overview
  58. 4.10.3 Sanofi Pasteur, Inc Attenuated Vaccine for Human Rabies Sales, Revenue and Gross Margin (2021-2026)
  59. 4.10.4 Sanofi Pasteur, Inc Attenuated Vaccine for Human Rabies Product Portfolio
  60. 4.10.5 Sanofi Pasteur, Inc Recent Developments
  61. 4.11 Pfizer Inc
  62. 4.11.1 Pfizer Inc Company Information
  63. 4.11.2 Pfizer Inc Business Overview
  64. 4.11.3 Pfizer Inc Attenuated Vaccine for Human Rabies Sales, Revenue and Gross Margin (2021-2026)
  65. 4.11.4 Pfizer Inc Attenuated Vaccine for Human Rabies Product Portfolio
  66. 4.11.5 Pfizer Inc Recent Developments
  67. 4.12 Novartis AG
  68. 4.12.1 Novartis AG Company Information
  69. 4.12.2 Novartis AG Business Overview
  70. 4.12.3 Novartis AG Attenuated Vaccine for Human Rabies Sales, Revenue and Gross Margin (2021-2026)
  71. 4.12.4 Novartis AG Attenuated Vaccine for Human Rabies Product Portfolio
  72. 4.12.5 Novartis AG Recent Developments
  73. 4.13 Merck & Co Inc
  74. 4.13.1 Merck & Co Inc Company Information
  75. 4.13.2 Merck & Co Inc Business Overview
  76. 4.13.3 Merck & Co Inc Attenuated Vaccine for Human Rabies Sales, Revenue and Gross Margin (2021-2026)
  77. 4.13.4 Merck & Co Inc Attenuated Vaccine for Human Rabies Product Portfolio
  78. 4.13.5 Merck & Co Inc Recent Developments
  79. 4.14 GlaxoSmithKline
  80. 4.14.1 GlaxoSmithKline Company Information
  81. 4.14.2 GlaxoSmithKline Business Overview
  82. 4.14.3 GlaxoSmithKline Attenuated Vaccine for Human Rabies Sales, Revenue and Gross Margin (2021-2026)
  83. 4.14.4 GlaxoSmithKline Attenuated Vaccine for Human Rabies Product Portfolio
  84. 4.14.5 GlaxoSmithKline Recent Developments
  85. 4.15 Cadila Pharmaceuticals Ltd
  86. 4.15.1 Cadila Pharmaceuticals Ltd Company Information
  87. 4.15.2 Cadila Pharmaceuticals Ltd Business Overview
  88. 4.15.3 Cadila Pharmaceuticals Ltd Attenuated Vaccine for Human Rabies Sales, Revenue and Gross Margin (2021-2026)
  89. 4.15.4 Cadila Pharmaceuticals Ltd Attenuated Vaccine for Human Rabies Product Portfolio
  90. 4.15.5 Cadila Pharmaceuticals Ltd Recent Developments
5 Global Attenuated Vaccine for Human Rabies Market Scenario by Region
  1. 5.1 Global Attenuated Vaccine for Human Rabies Market Size by Region: 2021 VS 2025 VS 2032
  2. 5.2 Global Attenuated Vaccine for Human Rabies Sales by Region: 2021-2032
  3. 5.2.1 Global Attenuated Vaccine for Human Rabies Sales by Region: 2021-2026
  4. 5.2.2 Global Attenuated Vaccine for Human Rabies Sales by Region: 2027-2032
  5. 5.3 Global Attenuated Vaccine for Human Rabies Revenue by Region: 2021-2032
  6. 5.3.1 Global Attenuated Vaccine for Human Rabies Revenue by Region: 2021-2026
  7. 5.3.2 Global Attenuated Vaccine for Human Rabies Revenue by Region: 2027-2032
  8. 5.4 North America Attenuated Vaccine for Human Rabies Market Facts & Figures by Country
  9. 5.4.1 North America Attenuated Vaccine for Human Rabies Market Size by Country: 2021 VS 2025 VS 2032
  10. 5.4.2 North America Attenuated Vaccine for Human Rabies Sales by Country (2021-2032)
  11. 5.4.3 North America Attenuated Vaccine for Human Rabies Revenue by Country (2021-2032)
  12. 5.4.4 United States
  13. 5.4.5 Canada
  14. 5.5 Europe Attenuated Vaccine for Human Rabies Market Facts & Figures by Country
  15. 5.5.1 Europe Attenuated Vaccine for Human Rabies Market Size by Country: 2021 VS 2025 VS 2032
  16. 5.5.2 Europe Attenuated Vaccine for Human Rabies Sales by Country (2021-2032)
  17. 5.5.3 Europe Attenuated Vaccine for Human Rabies Revenue by Country (2021-2032)
  18. 5.5.4 Germany
  19. 5.5.5 France
  20. 5.5.6 U.K.
  21. 5.5.7 Italy
  22. 5.5.8 Netherlands
  23. 5.6 Asia Pacific Attenuated Vaccine for Human Rabies Market Facts & Figures by Country
  24. 5.6.1 Asia Pacific Attenuated Vaccine for Human Rabies Market Size by Country: 2021 VS 2025 VS 2032
  25. 5.6.2 Asia Pacific Attenuated Vaccine for Human Rabies Sales by Country (2021-2032)
  26. 5.6.3 Asia Pacific Attenuated Vaccine for Human Rabies Revenue by Country (2021-2032)
  27. 5.6.4 China
  28. 5.6.5 Japan
  29. 5.6.6 South Korea
  30. 5.6.7 India
  31. 5.6.8 Australia
  32. 5.6.9 China Taiwan
  33. 5.6.10 Southeast Asia
  34. 5.7 South America Attenuated Vaccine for Human Rabies Market Facts & Figures by Country
  35. 5.7.1 South America Attenuated Vaccine for Human Rabies Market Size by Country: 2021 VS 2025 VS 2032
  36. 5.7.2 South America Attenuated Vaccine for Human Rabies Sales by Country (2021-2032)
  37. 5.7.3 South America Attenuated Vaccine for Human Rabies Revenue by Country (2021-2032)
  38. 5.7.4 Mexico
  39. 5.7.5 Brazil
  40. 5.7.6 Argentina
  41. 5.8 Middle East and Africa Attenuated Vaccine for Human Rabies Market Facts & Figures by Country
  42. 5.8.1 Middle East and Africa Attenuated Vaccine for Human Rabies Market Size by Country: 2021 VS 2025 VS 2032
  43. 5.8.2 Middle East and Africa Attenuated Vaccine for Human Rabies Sales by Country (2021-2032)
  44. 5.8.3 Middle East and Africa Attenuated Vaccine for Human Rabies Revenue by Country (2021-2032)
  45. 5.8.4 Turkey
  46. 5.8.5 Saudi Arabia
  47. 5.8.6 UAE
6 Segment by Type
  1. 6.1 Global Attenuated Vaccine for Human Rabies Sales by Type (2021-2032)
  2. 6.1.1 Global Attenuated Vaccine for Human Rabies Sales by Type (2021-2032) & (K Units)
  3. 6.1.2 Global Attenuated Vaccine for Human Rabies Sales Market Share by Type (2021-2032)
  4. 6.2 Global Attenuated Vaccine for Human Rabies Revenue by Type (2021-2032)
  5. 6.2.1 Global Attenuated Vaccine for Human Rabies Sales by Type (2021-2032) & (US$ Million)
  6. 6.2.2 Global Attenuated Vaccine for Human Rabies Revenue Market Share by Type (2021-2032)
  7. 6.3 Global Attenuated Vaccine for Human Rabies Price by Type (2021-2032)
7 Segment by Application
  1. 7.1 Global Attenuated Vaccine for Human Rabies Sales by Application (2021-2032)
  2. 7.1.1 Global Attenuated Vaccine for Human Rabies Sales by Application (2021-2032) & (K Units)
  3. 7.1.2 Global Attenuated Vaccine for Human Rabies Sales Market Share by Application (2021-2032)
  4. 7.2 Global Attenuated Vaccine for Human Rabies Revenue by Application (2021-2032)
  5. 7.2.1 Global Attenuated Vaccine for Human Rabies Sales by Application (2021-2032) & (US$ Million)
  6. 7.2.2 Global Attenuated Vaccine for Human Rabies Revenue Market Share by Application (2021-2032)
  7. 7.3 Global Attenuated Vaccine for Human Rabies Price by Application (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
  1. 8.1 Attenuated Vaccine for Human Rabies Value Chain Analysis
  2. 8.1.1 Attenuated Vaccine for Human Rabies Key Raw Materials
  3. 8.1.2 Raw Materials Key Suppliers
  4. 8.1.3 Attenuated Vaccine for Human Rabies Production Mode & Process
  5. 8.2 Attenuated Vaccine for Human Rabies Sales Channels Analysis
  6. 8.2.1 Direct Comparison with Distribution Share
  7. 8.2.2 Attenuated Vaccine for Human Rabies Distributors
  8. 8.2.3 Attenuated Vaccine for Human Rabies Customers
9 Global Attenuated Vaccine for Human Rabies Analyzing Market Dynamics
  1. 9.1 Attenuated Vaccine for Human Rabies Industry Trends
  2. 9.2 Attenuated Vaccine for Human Rabies Industry Drivers
  3. 9.3 Attenuated Vaccine for Human Rabies Industry Opportunities and Challenges
  4. 9.4 Attenuated Vaccine for Human Rabies Industry Restraints
10 Report Conclusion
    11 Disclaimer

      GET THE RESEARCH

      Choose your license.

      Choose who needs access.
      All options are for this report and research series.

      Compare access permissions.

      Single User License
      One named user. Individual access.
      Multi User License
      Up to 5 users in the same department.
      Enterprise License
      Organization-wide access within the agreed license.

      Access applies to the purchased edition. Later editions are separate purchases.

      License options
      $2,950USD
      Buy now

      PDF by email within 3–5 working days after payment confirmation.

      Talk to an analyst
      APO Research
      Talk to an analyst